- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00873574
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders (SMP)
Molecular Study of Factors Involved in JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Myeloproliferative disorders (MPD) are rare malignant diseases of the bone marrow characterized by a proliferation of differentiated blood cells during a long time and a possible transformation in an acute leukaemia.
The recent identification of a recurrent activating tyrosine kinase mutation V617F in the JAK2 gene provides a breakthrough in the understanding of the molecular mechanisms of these diseases. It can't explain nevertheless the phenotypic diversity of MPD and the occurrence of familial aggregations. The investigators have shown actually that the mutation V617F is a somatic one which is variably expressed among patients in the same family.Other somatic mutations and inherited factors, still unknown, may explain these discrepancies. JAK-STAT pathway has an essential role in non-CML MPD as was shown by the functional consequences of the V617F JAK2 mutation. Therefore, the investigators will focus our study on the genes encoding factors implicated in this signalling pathway. Two genetic approaches will be used: 1-study of known polymorphisms (SNP) of theses genes involved in the JAK-STAT pathway; 2-search of rare mutations located in specific regions (binding domain…) of candidate genes.The study is a national multicenter research based on the national network (55 centers) that the investigators have organized with the help of the French Society Of Hematology in 1998. The investigators propose to include 120 families defined by the presence of at least 2 cases of non CML MPD (WHO and PVSG criteria).The investigators have already collected 60 families (affected cases and control subject); the other 60 will be included in the next two years. In each family, only the two patients with MPD and one control will be included ( all the subjects above 18 years old). Peripheral blood samples (35ml) and buccal swabs will be collected for each subject. Hematologists and ONCOGENETICIANS will include the families, collect all the clinical and biological data and perform the collection of biological material from each subject included in the study according to approved rules.All the data will be anonymously registered on Access data base. Hematological studies will be done in the Immuno-Hematological Laboratory in Saint ANTOINE. Genetic studies will be conducted in the Genetic Department of Saint ANTOINE Hospital now transferred to Pitie-Salpetriere Hospital in Paris. The genetic study will be based on the analysis of 120 unrelated familial SMP cases (randomised) and 120 controls. The investigators will study 10 genes involved in the JAK-STAT pathway ( cytokine receptors, Janus kinases, regulatory factors).The genotyping of SNPs, selected from HAPMAP and CGEMS databases will be performed by quantitative PCR. The investigators plan to analyze 50 SNPs per subject i.e. 24000 genotypes (duplicate points). The analysis will be based on the allelic frequency comparison in the two groups using a bilateral paired t-test; 120 pairs of subjects (case control) allow to detect a 0.6 deviation standard of allelic frequency between cases and controls (alpha = 5%, beta = 10%). The search for rare mutations will be done by genomic sequencing of particular regions in candidates genes in the 120 affected cases.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75012
- Department of Hematology, Hospital Saint Antoine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients affected with polycythemia vera, essential thrombocythemia or primary myelofibrosis
- Familial cases
- Subjects above 18 years old
- Non affected controls
Exclusion Criteria:
- patients with chronic myeloid leukaemia
- subjects under 18 years old
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
2 patients with MPD for each family.
One case for each family will be randomised ; the cohort will be of 120 patients.
|
Peripheral blood samples (35 ml) and buccal swabs
|
2
1 control for each family
|
Peripheral blood samples (35 ml) and buccal swabs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Allelic frequency comparison between the 2 cohorts
Time Frame: At the inclusion visit
|
At the inclusion visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Undescribed gene mutations.
Time Frame: At the inclusion visit
|
At the inclusion visit
|
Collaborators and Investigators
Investigators
- Principal Investigator: Albert NAJMAN, MD PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AOR 07014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloproliferative Disorders
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedLeukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative DiseasesUnited States
-
Sociedad de Lucha Contra el Cáncer del EcuadorCompletedMyeloproliferative Disorders | Myeloproliferative Neoplasm | Myeloproliferative Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Myeloproliferative Disease, Not ClassifiedEcuador
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedMyelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise SpecifiedUnited States
-
University of California, IrvineCompletedMyeloproliferative NeoplasmUnited States
-
Fondazione per la Ricerca Ospedale MaggioreCompletedMyeloproliferative NeoplasmItaly, United Kingdom, Germany, France, United States, Spain, Canada
-
Safaa AA KhaledUnknownMyeloproliferative Neoplasm
-
M.D. Anderson Cancer CenterCTI BioPharmaTerminatedMyeloproliferative DiseasesUnited States
-
Assiut UniversityUnknownMyeloproliferative Neoplasm
Clinical Trials on Blood samples and buccal swabs
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Montefiore Medical Center; American Cancer Society...Completed
-
Larimar Therapeutics, Inc.Clinilabs, Inc.CompletedHealthy Volunteers | Friedreich AtaxiaUnited States
-
Larimar Therapeutics, Inc.Children's Hospital of PhiladelphiaCompletedFriedreich AtaxiaUnited States
-
University Medical Center GoettingenDepartment of Medicine II, University Hospital Rostock; Medical Department... and other collaboratorsRecruiting
-
University Hospital Inselspital, BerneActive, not recruiting
-
Centre Hospitalier Universitaire de Saint EtienneSanofi Pasteur, a Sanofi CompanyCompleted
-
Assistance Publique - Hôpitaux de ParisPasteur Institute of ParisRecruiting
-
Oncology Institute of Southern SwitzerlandInstitute of Oncology ResearchRecruitingEpithelial Ovarian CancerSwitzerland
-
Cliniques universitaires Saint-Luc- Université...RecruitingSARS-CoV-2 Infection | Influenza Viral InfectionsBelgium
-
Centre Hospitalier Universitaire de NīmesNantes University HospitalCompletedGynecological SurgeryFrance